NervGen Reports Third Quarter 2026 Financial Results and Provides Business Updates
MIAMI, Nov. 16, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today reported financial results for the third quarter ended September 30, 2026, and provided business updates.